BioPorto A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THOXF research report →
Companybioporto.com
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships.
- CEO
- Carsten Buhl
- IPO
- 2019
- Employees
- 48
- HQ
- Hellerup, DK
Price Chart
Valuation
- Market Cap
- $73.77M
- P/E
- -7.02
- P/S
- 14.32
- P/B
- 9.15
- EV/EBITDA
- -6.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.44%
- Op Margin
- -213.70%
- Net Margin
- -203.83%
- ROE
- -166.86%
- ROIC
- -114.38%
Growth & Income
- Revenue
- $40.20M · 10.91%
- Net Income
- $-81,930,998 · -20.06%
- EPS
- $-0.15 · 11.76%
- Op Income
- $-85,898,988
- FCF YoY
- 8.39%
Performance & Tape
- 52W High
- $0.31
- 52W Low
- $0.15
- 50D MA
- $0.15
- 200D MA
- $0.23
- Beta
- 1.28
- Avg Volume
- 15.99K
Get TickerSpark's AI analysis on THOXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our THOXF Coverage
We haven't published any research on THOXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THOXF Report →